Literature DB >> 6199591

Effects of selective and nonselective beta-agonists on plasma potassium and norepinephrine.

H H Vincent, F Boomsma, A J Man in't Veld, F H Derkx, G J Wenting, M A Schalekamp.   

Abstract

The effects of graded infusions of the beta-agonists isoproterenol (nonselective), l-prenalterol (beta 1-selective), and salbutamol (beta 2-selective) on plasma potassium and norepinephrine were compared in subjects with borderline hypertension. Potassium levels fell with all three agonists, and norepinephrine levels rose with isoproterenol and salbutamol. These effects on potassium and norepinephrine were closely correlated and occurred at the same dose ranges as the cardiovascular responses. The fall in plasma potassium was probably caused by activation of beta-receptors, mainly on skeletal muscle, with subsequent stimulation of active sodium-potassium transport across the cellular membrane. The rise in plasma norepinephrine may have been due to activation of beta-receptors on sympathetic nerve endings. Activation of these presynaptic receptors is known to enhance the release of norepinephrine during nerve stimulation. For a given increase in heart rate and cardiac contractility, as measured by the heart rate-corrected duration of total electromechanical systole, which are mainly beta 1-responses, the effects on potassium and norepinephrine were in the order: salbutamol greater than isoproterenol greater than prenalterol. beta-Blockade with propranolol (nonselective), 80 mg four times a day, or atenolol (beta 1-selective), 100 mg once a day, antagonized the hypokalemic effect of isoproterenol as well as the rise in norepinephrine, but when isoproterenol was infused in doses high enough to overcome the blockade of the heart rate response, the effects on norepinephrine and potassium were abolished by propranolol and not by atenolol. Thus, the receptors in question appear to be of the beta 2-subtype.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6199591

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  13 in total

1.  Hypokalaemia and other non-bronchial effects of inhaled fenoterol and salbutamol: a placebo-controlled dose-response study in healthy volunteers.

Authors:  M Scheinin; M Koulu; E Laurikainen; H Allonen
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

2.  Hypokalemia in a pediatric patient on continuous renal replacement therapy: Answers.

Authors:  Alexandra Idrovo; Ayse Akcan-Arikan; Rossana Malatesta-Muncher; Leyat Tal
Journal:  Pediatr Nephrol       Date:  2019-12       Impact factor: 3.714

3.  The effects of a single dose of dilevalol on [3H]-noradrenaline plasma kinetics and plasma lipoprotein cholesterol concentrations.

Authors:  L G Howes; P R Rowe; H Krum; W J Louis
Journal:  Br J Clin Pharmacol       Date:  1990-03       Impact factor: 4.335

4.  Haemodynamic, metabolic, and lymphocyte beta 2-adrenoceptor changes following chronic beta-adrenoceptor antagonism.

Authors:  K Whyte; C R Jones; C A Howie; N Deighton; D J Sumner; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 5.  Salbutamol in the 1980s. A reappraisal of its clinical efficacy.

Authors:  A H Price; S P Clissold
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

6.  Epinephrine facilitates neurogenic vasoconstriction in humans.

Authors:  J S Floras; P E Aylward; R G Victor; A L Mark; F M Abboud
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

7.  Effect of CGP 17/582, a selective beta-adrenoceptor antagonist, on the haemodynamic and hypokalaemic response to adrenaline.

Authors:  K F Whyte; P J De Vane; R Whitesmith; A Kelman; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

8.  The cardiovascular effects of beta adrenergic agonist drugs administered by nebulisation.

Authors:  A Flatt; J Crane; G Purdie; T Kwong; R Beasley; C Burgess
Journal:  Postgrad Med J       Date:  1990-02       Impact factor: 2.401

9.  Beta adrenoreceptor subtype cross regulation in the human heart.

Authors:  J A Hall; A Ferro; J E Dickerson; M J Brown
Journal:  Br Heart J       Date:  1993-04

10.  The assessment of the beta-adrenoceptor blocking activity and cardioselectivity of Koe 3290 in normal subjects.

Authors:  T H Pringle; A J McNeill; J G Riddell; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.